Progress in molecular biology and translational science最新文献_第5页

Advances in CRISPR-Cas systems for epigenetics. 用于表观遗传学的 CRISPR-Cas 系统的进展。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-08-22 DOI: 10.1016/bs.pmbts.2024.07.003

Mahnoor Ilyas, Qasim Shah, Alvina Gul, Huzaifa Ibrahim, Rania Fatima, Mustafeez Mujtaba Babar, Jayakumar Rajadas

{"title":"Advances in CRISPR-Cas systems for epigenetics.","authors":"Mahnoor Ilyas, Qasim Shah, Alvina Gul, Huzaifa Ibrahim, Rania Fatima, Mustafeez Mujtaba Babar, Jayakumar Rajadas","doi":"10.1016/bs.pmbts.2024.07.003","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.07.003","url":null,"abstract":"The CRISPR-Cas9 method has revolutionized the gene editing. Epigenetic changes, including DNA methylation, RNA modification, and changes in histone proteins, have been intensively studied and found to play a key role in the pathogenesis of human diseases. CRISPR-While the utility of DNA and chromatin modifications, known as epigenetics, is well understood, the functional significance of various alterations of RNA nucleotides has recently gained attention. Recent advancements in improving CRISPR-based epigenetic modifications has resulted in the availability of a powerful source that can selectively modify DNA, allowing for the maintenance of epigenetic memory over several cell divisions. Accurate identification of DNA methylation at specific locations is crucial for the prompt detection of cancer and other diseases, as DNA methylation is strongly correlated to the onset as well as the advancement of such conditions. Genetic or epigenetic perturbations can disrupt the regulation of imprinted genes, resulting in the development of diseases. When histone code editors and DNA de-/ methyltransferases are coupled with catalytically inactive Cas9 (dCas9), and CRISPRa and CRISPRi, they demonstrate excellent efficacy in editing the epigenome of eukaryotic cells. Advancing and optimizing the extracellular delivery platform can, hence, further facilitate the manipulation of CRISPR-Cas9 gene editing technique in upcoming clinical studies. The current chapter focuses on how the CRISP/ Cas9 system provides an avenue for the epigenetic modifications and its employability for human benefit.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"208 ","pages":"185-209"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in CRISPR-Cas systems for fungal infections. 用于真菌感染的 CRISPR-Cas 系统的进展。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-08-21 DOI: 10.1016/bs.pmbts.2024.07.006

Avinash Singh, Monisa Anwer, Juveriya Israr, Ajay Kumar

{"title":"Advances in CRISPR-Cas systems for fungal infections.","authors":"Avinash Singh, Monisa Anwer, Juveriya Israr, Ajay Kumar","doi":"10.1016/bs.pmbts.2024.07.006","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.07.006","url":null,"abstract":"Fungi contain a wide range of bioactive secondary metabolites (SMs) that have numerous applications in various fields, including agriculture, medicine, human health, and more. It is common for genes responsible for the production of secondary metabolites (SMs) to form biosynthetic gene clusters (BGCs). The identification and analysis of numerous unexplored gene clusters (BGCs) and their corresponding substances (SMs) has been significantly facilitated by the recent advancements in genomic and genetic technologies. Nevertheless, the exploration of secondary metabolites with commercial value is impeded by a variety of challenges. The emergence of modern CRISPR/Cas technologies has brought about a paradigm shift in fungal genetic engineering, significantly streamlining the process of discovering new bioactive compounds. This study begins with an examination of fungal biosynthetic gene clusters (BGCs) and their interconnections with the secondary metabolites (SMs) they generate. Following that, a brief summary of the conventional methods employed in fungal genetic engineering is provided. This study explores various sophisticated CRISPR/Cas-based methodologies and their utilization in examining the synthesis of secondary metabolites (SMs) in fungi. The chapter provides an in-depth analysis of the limitations and obstacles encountered in CRISPR/Cas-based systems when applied to fungal genetic engineering. It also proposes promising avenues for future research to optimize the efficiency of these systems.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"208 ","pages":"83-107"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Magnetic nanoparticles: An emerging nanomedicine for cancer immunotherapy. 磁性纳米粒子：用于癌症免疫疗法的新兴纳米药物。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.pmbts.2024.03.017

Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon, Charupong Saengboonmee

引用次数: 0

Biosafety and regulatory issues of RNA therapeutics. RNA 疗法的生物安全和监管问题。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-01-24 DOI: 10.1016/bs.pmbts.2023.12.008

Hue Vu Thi, Lan-Anh Nguyen Thi, Thuy Linh Tang, Dinh-Toi Chu

{"title":"Biosafety and regulatory issues of RNA therapeutics.","authors":"Hue Vu Thi, Lan-Anh Nguyen Thi, Thuy Linh Tang, Dinh-Toi Chu","doi":"10.1016/bs.pmbts.2023.12.008","DOIUrl":"10.1016/bs.pmbts.2023.12.008","url":null,"abstract":"RNA therapy has recently emerged as a therapy targeting specific genes or proteins. With its outstanding advantages, this therapy has opened promising doors for treating and preventing diseases. The great application potential has driven the need for a comprehensive understanding of these therapies, particularly on biosafety and regulatory issues. This chapter began by discussing the risks to RNA therapy, such as off-target effects, immunogenicity and immune responses, and long-term effects. Since then, this therapy's intricate landscape of biosafety issues has been elucidated. Common biosecurity measures applied around the world have also been reviewed. In addition, this chapter emphasized the importance of regulations and laws in applying RNA therapy to prevent and treat human and animal diseases. At the same time, the current legal regulations in the world for RNA therapies have also been thoroughly discussed. To sum up, this chapter has provided a comprehensive perspective on biosafety and regulatory issues for developing RNA therapies. Understanding the biosafety and regulatory issues in RNA therapy can help researchers use this promising new technology safely and effectively in the future.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"204 ","pages":"311-329"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 pathogenesis. COVID-19 的发病机制。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-01-05 DOI: 10.1016/bs.pmbts.2023.07.001

Asiya Kamber Zaidi, Rohan Bir Singh, Syed A A Rizvi, Puya Dehgani-Mobaraki, Nicola Palladino

引用次数: 0

Prediction of protein aggregation. 预测蛋白质聚集

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-04-16 DOI: 10.1016/bs.pmbts.2024.03.005

Kavyan Khalili, Farnoosh Farzam, Bahareh Dabirmanesh, Khosro Khajeh

引用次数: 0

Drug repurposing for bacterial infections. 针对细菌感染的药物再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-11 DOI: 10.1016/bs.pmbts.2024.03.031

Mahnoor Ilyas, Muhammad Saad Latif, Alvina Gul, Mustafeez Mujtaba Babar, Jayakumar Rajadas

{"title":"Drug repurposing for bacterial infections.","authors":"Mahnoor Ilyas, Muhammad Saad Latif, Alvina Gul, Mustafeez Mujtaba Babar, Jayakumar Rajadas","doi":"10.1016/bs.pmbts.2024.03.031","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.03.031","url":null,"abstract":"Repurposing pharmaceuticals is a technique used to find new, alternate clinical applications for approved drug molecules. It may include altering the drug formulation, route of administration, dose or the dosage regimen. The process of repurposing medicines starts with screening libraries of previously approved drugs for the targeted disease condition. If after an the initial in silico, in vitro or in vivo experimentation, the molecule has been found to be active against a particular target, the molecule is considered as a good candidate for clinical trials. As the safety profile of such molecules is available from the previous data, significant time and resources are saved. These advantages of drug repurposing approach make it especially helpful for finding treatments for rapidly evolving conditions including bacterial infections. An ever-increasing incidence of antimicrobial resistance, owing to the mutations in bacterial genome, leads to therapeutic failure of many approved antibiotics. Repurposing the approved drug molecules for use as antibiotics can provide an effective means for the combating life-threatening bacterial diseases. A number of drugs have been considered for drug repurposing against bacterial infections. These include, but are not limited to, Auranofin, Closantel, and Toremifene that have been repurposed for various infections. In addition, the reallocation of route of administration, redefining dosage regimen and reformulation of dosage forms have also been carried out for repurposing purpose. The current chapter addresses the drug discovery and development process with relevance to repurposing against bacterial infections.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"1-21"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug repurposing for fungal infections. 针对真菌感染的药物再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-13 DOI: 10.1016/bs.pmbts.2024.04.002

Anshu Mathuria, Namra Ali, Naina Kataria, Indra Mani

{"title":"Drug repurposing for fungal infections.","authors":"Anshu Mathuria, Namra Ali, Naina Kataria, Indra Mani","doi":"10.1016/bs.pmbts.2024.04.002","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.04.002","url":null,"abstract":"The rise of multidrug-resistant bacteria is a well-recognized threat to world health, necessitating the implementation of effective treatments. This issue has been identified as a top priority on the global agenda by the World Health Organization. Certain strains, such as Candida glabrata, Candida krusei, Candida lusitaniae, Candida auris, select cryptococcal species, and opportunistic Aspergillus or Fusarium species, have significant intrinsic resistance to numerous antifungal medicines. This inherent resistance and subsequent suboptimal clinical outcomes underscore the critical imperative for enhanced therapeutic alternatives and management protocols. The challenge of effectively treating fungal infections, compounded by the protracted timelines involved in developing novel drugs, underscores the pressing need to explore alternative therapeutic avenues. Among these, drug repurposing emerges as a particularly promising and expeditious solution, providing cost-effective solutions and safety benefits. In the fight against life-threatening resistant fungal infections, the idea of repurposing existing medications has encouraged research into both established and new compounds as a last-resort therapy. This chapter seeks to provide a comprehensive overview of contemporary antifungal drugs, as well as their key resistance mechanisms. Additionally, it seeks to provide insight into the antimicrobial properties of non-traditional drugs, thereby offering a holistic perspective on the evolving landscape of antifungal therapeutics.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"59-78"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biotechnological applications of amyloid fibrils. 淀粉样纤维的生物技术应用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-04-14 DOI: 10.1016/bs.pmbts.2024.04.001

Mohsen Nabi Afjadi, Fatemeh Aziziyan, Farnoosh Farzam, Bahareh Dabirmanesh

引用次数: 0

Preface. 序言

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 DOI: 10.1016/S1877-1173(24)00184-4

Vijai Singh

引用次数: 0